Main – An updated COVID-19 vaccine is tailored by Pfizer-BionTech to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older. You should NOT get COMIRNATY® (COVID-19 Vaccine, mRNA) if you had a severe allergic reaction to a previous dose of COMIRNATY or any Pfizer-BioNTech COVID-19 vaccine or to any ingredient …
Laval – In June 2022, the Government of Canada established a long-term agreement with Moderna for the domestic production of messenger RNA (mRNA) vaccines in Canada. The negotiations began in 2021, during the depths of the COVID-19 pandemic, as the country faced intense global competition to secure vaccines. This global supply chain vulnerability showcased the need to ensure domestic capacity …
TORONTO – Moderna Canada announces the appointment of Roger-Ketcha Ngassam as the Manufacturing Site Head for its mRNA vaccine manufacturing facility. A seasoned leader with local roots and extensive international experience, Roger will oversee the planning, construction, and execution at Moderna’s Good Manufacturing Practice (GMP) site, currently under construction in Laval, Quebec. He will also lead the local team recruitment …
Vaccines manufactured at Moderna’s state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol’s Ontario-based facility Fill-finish agreement will secure domestic end-to-end vaccine production and ensures rapid response capabilities for future pandemic readiness for Canadians TORONTO-Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a long-term agreement with Ontario-based Novocol Pharma, a leading …
